Gossamer Bio Investors Reminder for Class Action Filing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy GOSS?
Source: Globenewswire
- Filing Deadline: Investors in Gossamer Bio must file a lead plaintiff motion by June 1, 2026, to participate in the class action lawsuit concerning securities purchased between June 16, 2025, and February 20, 2026, reflecting strong investor response to the company's performance failure.
- Study Failure Announcement: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study for pulmonary arterial hypertension failed to meet its primary endpoint, resulting in an 80.3% stock price drop to $0.42 per share, indicating a severe loss of investor confidence in the company's future prospects.
- Allegations of Misrepresentation: The lawsuit alleges that throughout the class period, the company made materially false and misleading statements and failed to disclose the heavily treated lower-risk patient population in Latin America, which contributed to the poor study results and exacerbated investor losses.
- Investor Rights Protection: Investors who purchased Gossamer securities during the class period may apply to be lead plaintiffs before the deadline to recover losses due to the company's misleading statements, highlighting the legal system's role in protecting investor rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.451
Low
10.00
Averages
12.33
High
15.00
Current: 0.451
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) is facing allegations for failing to disclose critical facts regarding its clinical trial failures during the class period from June 16, 2025, to February 20, 2026, misleading investors, with a lead plaintiff motion deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy & Digital (NASDAQ:NUAI) is accused of overstating progress on its Texas data center project and engaging in fraudulent activities from November 6, 2024, to December 29, 2025, with investors needing to act by June 1, 2026, to protect their rights.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is under scrutiny for making false statements about its financial health during the period from April 22, 2025, to February 9, 2026, with a lead plaintiff motion deadline of June 5, 2026, potentially exposing investors to financial losses.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors holding shares in the aforementioned companies and suffering losses to contact their firm promptly to understand their legal rights and ensure proper representation in the class actions.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Gossamer Bio and certain officers, alleging violations of federal securities laws from June 16, 2025, to February 20, 2026, seeking to recover damages for affected investors.
- False Statements Allegation: The complaint claims that defendants misled investors by touting positive results from the PROSERA study while concealing significant adverse facts regarding the study's design at Latin American sites, resulting in artificially inflated stock prices that harmed investors.
- Investor Participation Call: Affected investors are encouraged to apply to be lead plaintiffs by June 1, 2026, allowing them to share in any recovery without needing to serve as lead plaintiffs, thus broadening participation in the lawsuit.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors in securities fraud class actions, emphasizing their commitment to restoring investor capital and ensuring corporate accountability in the marketplace.
See More
Faruqi & Faruqi Investigates Gossamer Bio Investor Losses
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Gossamer Bio, Inc. for investors who purchased securities between June 16, 2025, and February 20, 2026, indicating possible legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that June 1, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of investor participation in legal proceedings.
- Direct Contact Channels: Investors who suffered losses are encouraged to contact Faruq & Faruq partner Josh Wilson directly, with multiple contact options provided to facilitate consultations, demonstrating the firm's commitment to client service.
- Market Impact: This investigation could negatively affect Gossamer's stock price, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Gossamer Bio (NASDAQ:GOSS) securities between June 16, 2025, and February 20, 2026, alleging the company misled investors regarding its PROSERA study, causing shareholders to buy securities at artificially inflated prices.
- Study Results Fail: Gossamer's press release on February 23, 2026, revealed that its Phase 3 PROSERA study failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance (6MWD), which did not meet the required 0.025 alpha threshold, leading to an over 80% stock price drop in a single day.
- Investor Losses: Following the disappointing study results, Gossamer's stock plummeted from $2.13 per share on February 20, 2026, to $0.42 per share on February 23, 2026, resulting in significant losses for investors, with the class action aiming to seek compensation for affected shareholders.
- Opportunity to Participate: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by June 1, 2026, with Robbins LLP offering contingency fee representation, ensuring shareholders incur no costs in the litigation process.
See More
Gossamer Bio Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Gossamer Bio in the Southern District of California on behalf of investors who purchased securities between June 16, 2025, and February 20, 2026, indicating significant legal challenges for the company.
- False Information Allegations: The lawsuit alleges that Gossamer provided misleading information regarding its Phase 3 PROSERA study, particularly failing to control for placebo responses at Latin American testing sites, which led investors to buy shares at artificially inflated prices.
- Investor Rights Protection: Investors must apply by June 1, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the potential financial liabilities the company may face due to these allegations.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights and securities litigation, underscoring its expertise and influence in protecting investor interests.
See More
Class Action Notice for Gossamer Bio Investors
- Class Action Initiated: The Portnoy Law Firm has launched a class action on behalf of investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, with a deadline of June 1, 2026, for filing a lead plaintiff motion to protect their legal rights.
- False Information Disclosure: During the class period, Gossamer's management provided investors with positive information regarding its Phase 3 PROSERA study while concealing significant adverse facts about the study design, leading investors to purchase securities at artificially inflated prices.
- Study Results Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA study failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance (6MWD), which did not meet the required 0.025 alpha threshold, causing the stock price to plummet over 80% in a single day.
- Legal Recourse: The Portnoy Law Firm offers complimentary case evaluations for affected investors, aiming to assist them in recovering losses due to corporate wrongdoing, with the founding partner having recovered over $5.5 billion for aggrieved investors.
See More
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) is facing allegations for failing to disclose critical facts regarding its clinical trial failures during the class period from June 16, 2025, to February 20, 2026, misleading investors, with a lead plaintiff motion deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy & Digital (NASDAQ:NUAI) is accused of overstating progress on its Texas data center project and engaging in fraudulent activities from November 6, 2024, to December 29, 2025, with investors needing to act by June 1, 2026, to protect their rights.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is under scrutiny for making false statements about its financial health during the period from April 22, 2025, to February 9, 2026, with a lead plaintiff motion deadline of June 5, 2026, potentially exposing investors to financial losses.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors holding shares in the aforementioned companies and suffering losses to contact their firm promptly to understand their legal rights and ensure proper representation in the class actions.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Class Action Initiation: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Gossamer Bio and certain officers, alleging violations of federal securities laws from June 16, 2025, to February 20, 2026, seeking to recover damages for affected investors.
- False Statements Allegation: The complaint claims that defendants misled investors by touting positive results from the PROSERA study while concealing significant adverse facts regarding the study's design at Latin American sites, resulting in artificially inflated stock prices that harmed investors.
- Investor Participation Call: Affected investors are encouraged to apply to be lead plaintiffs by June 1, 2026, allowing them to share in any recovery without needing to serve as lead plaintiffs, thus broadening participation in the lawsuit.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors in securities fraud class actions, emphasizing their commitment to restoring investor capital and ensuring corporate accountability in the marketplace.
See More
Faruqi & Faruqi Investigates Gossamer Bio Investor Losses
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Gossamer Bio, Inc. for investors who purchased securities between June 16, 2025, and February 20, 2026, indicating possible legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that June 1, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of investor participation in legal proceedings.
- Direct Contact Channels: Investors who suffered losses are encouraged to contact Faruq & Faruq partner Josh Wilson directly, with multiple contact options provided to facilitate consultations, demonstrating the firm's commitment to client service.
- Market Impact: This investigation could negatively affect Gossamer's stock price, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Gossamer Bio (NASDAQ:GOSS) securities between June 16, 2025, and February 20, 2026, alleging the company misled investors regarding its PROSERA study, causing shareholders to buy securities at artificially inflated prices.
- Study Results Fail: Gossamer's press release on February 23, 2026, revealed that its Phase 3 PROSERA study failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance (6MWD), which did not meet the required 0.025 alpha threshold, leading to an over 80% stock price drop in a single day.
- Investor Losses: Following the disappointing study results, Gossamer's stock plummeted from $2.13 per share on February 20, 2026, to $0.42 per share on February 23, 2026, resulting in significant losses for investors, with the class action aiming to seek compensation for affected shareholders.
- Opportunity to Participate: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by June 1, 2026, with Robbins LLP offering contingency fee representation, ensuring shareholders incur no costs in the litigation process.
See More
Gossamer Bio Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Gossamer Bio in the Southern District of California on behalf of investors who purchased securities between June 16, 2025, and February 20, 2026, indicating significant legal challenges for the company.
- False Information Allegations: The lawsuit alleges that Gossamer provided misleading information regarding its Phase 3 PROSERA study, particularly failing to control for placebo responses at Latin American testing sites, which led investors to buy shares at artificially inflated prices.
- Investor Rights Protection: Investors must apply by June 1, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the potential financial liabilities the company may face due to these allegations.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights and securities litigation, underscoring its expertise and influence in protecting investor interests.
See More
Class Action Notice for Gossamer Bio Investors
- Class Action Initiated: The Portnoy Law Firm has launched a class action on behalf of investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, with a deadline of June 1, 2026, for filing a lead plaintiff motion to protect their legal rights.
- False Information Disclosure: During the class period, Gossamer's management provided investors with positive information regarding its Phase 3 PROSERA study while concealing significant adverse facts about the study design, leading investors to purchase securities at artificially inflated prices.
- Study Results Failure: On February 23, 2026, Gossamer announced that its Phase 3 PROSERA study failed to meet its primary endpoint, achieving only a +13.3 meter placebo-adjusted gain in six-minute walk distance (6MWD), which did not meet the required 0.025 alpha threshold, causing the stock price to plummet over 80% in a single day.
- Legal Recourse: The Portnoy Law Firm offers complimentary case evaluations for affected investors, aiming to assist them in recovering losses due to corporate wrongdoing, with the founding partner having recovered over $5.5 billion for aggrieved investors.
See More
